Efficacy and safety of topiramate in refractory epilepsy: A long-term prospective trial

Italian Journal of Neurological Sciences

Volumn 17, Issue 6, 1996, Pages 429-432

  Tartara, A ^a,c   Sartori, I ^a   Manni, R ^a   Galimberti, C A ^a   Di Fazio, M ^b   Perucca, E ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b Janssen Cilag SpA Italia   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

clinical trial; epilepsy; topiramate

Indexed keywords

TOPIRAMATE;

ADULT; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FATIGUE; HUMAN; IRRITABILITY; LENNOX GASTAUT SYNDROME; METABOLIC ACIDOSIS; SOMNOLENCE; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0030461527     PISSN: 03920461     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01997718     Document Type: Article

References (19)

1. BEN-MENACHEM E., HENRIKSEN O., DAM M. et al.: Double-blind, placebo-controlled trial of topiramate as addon therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539-543, 1996.
2. BEN-MENACHEM E.: Long-term follow-up of patients treated with topiramate for partial seizures. Epilepsia 36 (suppl. 3): S152, 1995.
3. COWELL P.O., COLES H.J., CRAWFORD P.M.: Topiramate as adjunctive therapy in patients with refractory epilepsy: A report of a long-term, open-label study. Epilepsia 376 (suppl. 3): S152, 1995.
4. FAUGHT E., WILDER B.J., RAMSAY R.E. et al.: Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 46: 1684-1690, 1996.
5. FINCHAM R.W., SCHOTTELIUS D.: Long-term therapy with topiramate in patients with partial seizures. Epilepsia 36 (suppl. 4): S56, 1995.
6. GUIDOLIN L., CANEVINI M.P., SGRO V. et al.: Topiramate as add-on therapy in drug-resistant partial epilepsy. Epilepsia 36 (suppl. 3): S151, 1995.
7. LUEF G., BAUER G.: Efficacy and safety of topiramate in drug-resistant epilepsies. Epilepsia 36 (suppl. 3): S151, 1995.
8. MARTINEZ-LAGE J., BEN-MENACHEM E., SHORVON S.D., WEBER M.: Double-blind, placebo-controlled trial of 400 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia 36 (suppl. 3): S149150, 1995.
9. MARYANOFF B.E., NORTEZ S.O., GARDOCKI J.F. et al.: Anticonvulsant O-alkyl-sulfamates in 2,3:4,5-bis-O-(lmethylethylidene)-beta-D-fructo-pyranose sulfamate and related compounds. J. Med. Chem. 30: 880-887, 1987.
10. MICHELUCCI R., PASSARELLI D., TASSINARI C.A.: Topiramate in the treatment of refractory epilepsy: A doubleblind study with long-term follow-up. Epilepsia 36 (suppl. 3): S150, 1995.
11. PAVKOVIC I., SACKELLARES C., BEYDOUN A.: Efficacy and safety of topiramate in epilepsy. Epilepsia 36 (suppl. 4): S55, 1995.
12. PRIVITERA M, FINCHAM R., PENRY J. et al.: Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 46: 1678-1683, 1996.
13. REIFE R.A., PLEDGER G.W.: Clinical efficacy of topiramate: U.S. and European experience. Adv. AED Ther. 1: 17-23, 1995.
14. REIFE R.A., PLEDGER G.W.: Safety of topiramate in clinical use. Adv. AED Ther. 1: 24-29, 1995.
15. SHANK R.P.: Preclinical profile of topiramate, a novel anticonvulsant. Adv. AED Ther. 1: 1-6, 1995.
16. SHANK R.P., GARDOCKI J.F., VAUGHT J.L. et al.: Topiramate: Preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 35: 450-460, 1994.
17. TASSINARI C.A., MICHELUCCI R., CHAUVEL P. et al.: Double-blind, placebo-controlled trial of Topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 37 (8): 763-768, 1996.
18. WASSERSTEIN A.G., RAK L, REIFE R.A.: Investigation of the mechanistic basis for topiramate-associated nephrolithiasis: Examination of urine and serum constituents. Epilepsia 36 (suppl. 3): S153, 1995.
19. WASSERSTEIN A.G., RAK L, REIFE R.A.: Nephrolithiasis during treatment with topiramate. Epilepsia 36 (suppl. 3): S153, 1995.